While much progress has been made in the fi eld of hematopoietic stem cel transplantation (HSCT), headway in the promotion of recovery folowing this procedure has been limited. Data regarding the potential of Chinese herbal medicine (CHM) for patients with hematologic disorders who received HSCT are gradualy increasing; however, these data are mostly in Chinese. Therefore, we set out to summarize the existing data. We searched PubMed, the Cochrane Library and the China National Knowledge Infrastructure and retrieved 9 clinical studies related to this group of patients, in whom CHM was used as an intervention. Of the 9 papers, 6 were published by the same group of researchers. The focus of the reviewed studies was heterogeneous, and the objectives varied widely. With the exception of one randomized control trial, al of the studies were retrospective and observational; the median number of patients was 11.5, with the largest study containing 104 patients. CHM treatment was largely divided into two stages: (1) pre-HSCT, which was initiated as soon as conditioning chemotherapy was administered and aimed to counterbalance the adverse effects of these potent agents; (2) post-HSCT, which began immediately after transplantation and was intended to promote engraftment, control graft-versus-host disease and prolong survival. In addition, the 9 Chinese materia medica most commonly prescribed (appearing in four studies) were: Shengdihuang (Rehmannia glutinosa), Baizhu (Atractylodes macrocephala), Renshen (Panax ginseng), Dangshen (Codonopsis pilosula), Maimendong (Ophiopogon japonicus), Danggui (Angelica sinensis), Taizishen (Pseudostelaria heterophyla), Huangqi (Astragalus membranaceus) and Ejiao (Equus asinus).